|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.460 USD | +2.41% |
|
+17.68% | +230.37% |
| Market Cap | 317M 278M 255M 238M 451M 30.23B 458M 3.06B 1.19B 14.86B 1.19B 1.17B 51.2B | P/E 2026 * |
-2.34x | P/E 2027 * | -2.67x |
|---|---|---|---|---|---|
| Enterprise Value | 106M 92.66M 85.15M 79.37M 151M 10.09B 153M 1.02B 397M 4.96B 398M 389M 17.09B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 5.85x |
| Free-Float |
77.16% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zentalis Pharmaceuticals, Inc.
| 1 day | +2.41% | ||
| 1 week | +17.68% | ||
| Current month | -8.04% | ||
| 1 month | +12.91% | ||
| 3 months | +69.58% | ||
| 6 months | +225.55% | ||
| Current year | +230.37% |
| 1 week | 3.96 |  | 5.11 |
| 1 month | 3.42 | | 5.11 |
| Current year | 1.32 | | 6.95 |
| 1 year | 1.15 | | 6.95 |
| 3 years | 1.01 | | 29.03 |
| 5 years | 1.01 | | 87.19 |
| 10 years | 1.01 | | 87.19 |
| Manager | Title | Age | Since |
|---|---|---|---|
Julia Eastland
CEO | Chief Executive Officer | 62 | 2024-11-12 |
| Director of Finance/CFO | - | 2024-11-12 | |
Ingmar Bruns
CTO | Chief Tech/Sci/R&D Officer | 51 | 2024-11-12 |
| Director | Title | Age | Since |
|---|---|---|---|
David Johnson
CHM | Chairman | 61 | 2022-05-15 |
Enoch Kariuki
BRD | Director/Board Member | 44 | 2021-02-08 |
Jan Skvarka
BRD | Director/Board Member | 59 | 2022-09-11 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-15 | Free | Chairman | 57,100 | 0.0802% | ||
| 06-15 | Free | Director | 57,100 | 0.0802% | ||
| 06-15 | Free | Director | 57,100 | 0.0802% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.41% | +17.68% | +259.68% | -84.19% | 317M | |
| +0.68% | +6.27% | +77.60% | +133.76% | 58.73B | |
| +2.32% | +5.89% | +76.81% | +99.20% | 53.92B | |
| +3.86% | +8.38% | -9.90% | -9.62% | 24.67B | |
| +4.30% | +6.82% | +13.60% | +428.91% | 24.19B | |
| +4.74% | +13.47% | +46.43% | +0.03% | 18.8B | |
| -0.29% | +8.57% | +44.17% | -27.58% | 17.61B | |
| 0.00% | +16.74% | +171.12% | +355.99% | 16.25B | |
| +3.50% | +4.92% | +26.07% | +192.26% | 14.04B | |
| +6.72% | +20.94% | +51.67% | - | 13.9B | |
| Average | +2.82% | +8.21% | +75.73% | +120.97% | 24.24B | |
| Weighted average by Cap. | +2.44% | +5.54% | +59.33% | +137.03% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 21.42M 18.72M 17.21M 16.04M 30.42M 2.04B 30.88M 207M 80.3M 1B 80.39M 78.66M 3.45B |
| Net income | -150M -131M -121M -112M -213M -14.29B -216M -1.45B -563M -7.03B -564M -551M -24.21B | -154M -135M -124M -115M -219M -14.66B -222M -1.48B -577M -7.2B -578M -565M -24.83B |
| Net Debt | -211M -185M -170M -158M -300M -20.14B -305M -2.04B -793M -9.9B -794M -777M -34.11B | -192M -168M -154M -144M -273M -18.3B -277M -1.85B -721M -9B -721M -706M -31B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-02 | US$4.460 | +2.41% | 583,661 |
| 26-07-01 | US$4.355 | -10.21% | 1,084,126 |
| 26-06-30 | US$4.850 | +5.21% | 1,853,549 |
| 26-06-29 | US$4.610 | +14.11% | 2,768,710 |
| 26-06-26 | US$4.040 | +6.60% | 7,490,437 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZNTL Stock
Select your edition
All financial news and data tailored to specific country editions
